The division includes company's polymer stabiliser business and production site in Panoli, Gujarat alongwith with the local Research and development team, SeQuent Scientific Ltd said in a filing to BSE.
Commenting on the development, SeQuent Scientific CEO Manish Gupta said: "With the completion of the sale of the specialty chemicals business, SeQuent has completed its restructuring and is poised to for aggressive growth in its focus areas of animal health business and niche human API business."
"The transaction was originally announced in April 2014 and has now achieved completion on completion of closing conditions and statuory/regulatory approvals," SeQuent Scientific said.
Shares of SeQuent Scientific Ltd today closed at Rs 384 apiece on the BSE, up 0.17 per cent from previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
